Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

Share Price is delayed by 15 minutes
Get Live Data
2,080.00    -62.00 (-2.89%)
Bid:
2,066.00
Ask:
2,070.00
Spread: 4.00 (0.194%)
Market Cap: £3.48b
JMAT Live PriceLast checked at - London Stock Exchange

Intraday Johnson Matthey Share Chart

AGM Statement

28 Jul 2017 07:00

RNS Number : 3642M
Johnson Matthey PLC
28 July 2017
Ā 

AGM Statement

First quarter trading in line with expectations and guidance for the full year unchanged

Ā 

Johnson Matthey will hold the company's Annual General Meeting today at 11.00 am in London and has issued the following trading statement ahead of the meeting.

Ā 

"The year has begun in line with our expectations. In the first quarter, we delivered low single-digit sales growth at constant rates and double-digit reported sales growth. The changes we have implemented are making the business more agile and efficient and our guidance for the full year is unchanged.

Ā 

Sales performance was strongest in our Clean Air sector as we again outperformed vehicle production in most markets. Strong growth of our HDD catalyst business was the main contributor with continued growth in Asia and Europe and following the anticipated improvement of the US Class 8 truck market. In the quarter, global light duty vehicle production declined although we outperformed in Europe as a result of the new business wins and sales of higher value technology which we had outlined in our 2017 results presentation. As we said in June, this will drive stronger growth in our LDV catalyst business over the remainder of our financial year.

Ā 

Sales in Efficient Natural Resources grew slightly. We delivered growth in our services businesses and while manufacturing sales declined we expect sales to recover in the second quarter. As anticipated, low levels of licensing activity and weak demand for equipment for use in the construction of formaldehyde plants led to lower sales in our chemicals business.

Ā 

Our Health business grew slightly as sales of APIs for products launched last year offset the decline we expect in the first half in sales of APIs for the treatment of ADHD. The performance of our new API products is encouraging and development of a broader API product portfolio will be the driver of improved medium-term performance for the sector.

Ā 

Changes introduced last year in China affected demand for our LFP battery materials and this led to the decline we saw in sales in New Markets. Our development of high nickel battery materials continues at pace and in addition, we have seen good growth in medical components as we look to build this business for the future.

Ā 

Cash generation and disciplined management of working capital remain a key focus for the business and working capital days were reduced compared to the same period last year. We are implementing the restructuring programme we announced in June which will deliver £10 million of cost savings in the second half of this year, contributing to the stronger underlying operating performance we expect to see in the second half. Through this restructuring programme we will generate a further £15 million of cost savings in 2018/19. As part of our capital markets day in September we will update the market on the work we are doing to enhance our functional excellence, making the whole business more agile.

Ā 

Our guidance for year ended 31st March 2018 is unchanged. We have momentum in sales and expect to build on this through the second quarter and into the second half to deliver our full year guidance. Our move to four sectors has improved our focus on the key growth trends and we remain confident that through inspiring science and enhancing life, Johnson Matthey will create value."

Ā 

Ends

Notes:

Unless otherwise stated, commentary in this statement is based on sales for the quarter ended 30th June 2017 and compares this quarter with the quarter ended 30th June 2016 at constant rates.

Ā 

Group structure

Johnson Matthey announced changes to the group structure on 20th April 2017 under which the group would be managed and report its results as four sectors. The results for the half year ended 30th September 2016 and year ended 31st March 2017 have been restated on the new basis of reporting sectors and are attached to this AGM statement.

Ā 

2017/18 restructuring charge

In the year ending 31st March 2018 Johnson Matthey expects to take a restructuring charge as part of the further changes it will make to improve efficiency. The charge is expected to be in the range of £50 million to £65 million, of which over half will be cash. It is expected to generate savings of around £25 million in a full year and benefit 2017/18 by approximately £10 million.

Ā 

In the preliminary announcement of results for the year ended 31st March 2017 on 1stĀ June 2017 Johnson Matthey gave the following outlook for the year ending 31stĀ MarchĀ 2018:

Ā· Sales growth, at constant rates, is expected to be broadly in line with the 6% growth delivered in the second half of the year ended 31st March 2017

Ā· The combination of stronger sales growth together with additional cost savings is expected to be offset by comparison against the 2016/17 US post-retirement medical benefit credit and by higher non-cash pension charges in 2017/18

Ā 

In the same announcement Johnson Matthey gave the following guidance for foreign exchange:

· At current exchange rates (£:$ 1.289; £:Euro 1.149; £:RMB 8.84) translational foreign exchange movements are expected to increase revenue by £133 million, sales by £66 million and operating profit by £13 million in the year ending 31st March 2018

Ā 

There has been no material change to this guidance.

Ā 

Capital markets day

Johnson Matthey will hold a capital markets day in London on 21stĀ September 2017. Further details will follow shortly.

Ā 

Ā 

Ā 

Enquiries:Ā 

Investor Relations

Simon McGough

Sarah Armstrong

Katharine Burrow

Ā 

Head of Investor Relations

Head of Investor Relations

Investor Relations Analyst

Ā 

020 7269 8235

020 7269 8426

020 7269 8444

Ā 

Media

Sally Jones

David Allchurch/Latika Shah

Ā 

Ā 

Director of Corporate Relations

Tulchan Communications

Ā 

Ā 

020 7269 8407

020 7353 4200

www.matthey.com

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

Group Structure

Ā 

Restatement of results for the half year ended 30th September 2016

Ā 

Ā 

Reported£m

Restated£m

Movements

Ā 

Ā 

Sales excluding precious metals

Ā 

Emission Control Technologies

1,054

Clean Air

1,054

Ā 

Process Technologies

265

Efficient Natural Resources

420

Excludes medical components sales of £29m and £5m of intra-sector sales (note 1)

Ā 

Precious Metal Products

189

Ā 

Fine Chemicals

133

Health

110

Excludes catalysis and chiral technologies (CCT) sales of £23m

Ā 

New Businesses

88

New Markets

144

Includes medical components and CCT sales and £4m of inter-sector sales (note 2)

Ā 

Eliminations

(53)

Eliminations

(52)

Ā 

Total

1,676

Total

1,676

Ā 

Ā 

Ā 

Underlying operating profit

Ā 

Emission Control Technologies

151.9

Clean Air

151.9

Ā 

Process Technologies

39.3

Efficient Natural Resources

73.4

Excludes medical components operating profit of £6.8m

Ā 

Precious Metal Products

40.9

Ā 

Fine Chemicals

26.9

Health

20.7

Excludes CCT operating profit of £6.2m

Ā 

New Businesses

(8.5)

New Markets

4.5

Includes medical components and CCT operating profit

Ā 

Corporate

(14.4)

Corporate

(14.4)

Ā 

Total

236.1

Total

236.1

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

Restatement of results for the year ended 31st March 2017

Reported£m

Restated£m

Movements

Sales excluding precious metals

Emission Control Technologies

2,224

Clean Air

2,224

Process Technologies

587

Efficient Natural Resources

919

Excludes medical components sales of £61m and £10m of intra-sector sales (note 1)

Precious Metal Products

403

Fine Chemicals

284

Health

236

Excludes catalysis and chiral technologies (CCT) sales of £48m

New Businesses

191

New Markets

308

Includes medical components and CCT sales and £8m of inter-sector sales (note 2)

Eliminations

(111)

Eliminations

(109)

Total

3,578

Total

3,578

Underlying operating profit

Emission Control Technologies

318.2

Clean Air

318.2

Process Technologies

90.4

Efficient Natural Resources

163.0

Excludes medical components operating profit of £13.8m

Precious Metal Products

86.4

Fine Chemicals

64.5

Health

51.7

Excludes CCT operating profit of £12.8m

Ā 

New Businesses

(14.4)

Ā 

New Markets

12.2

Includes medical components and CCT operating profit

Corporate

(31.8)

Corporate

(31.8)

Total

513.3

Total

513.3

Notes

1. Sales between Process Technologies and Precious Metal Product divisions

2. Medical component and CCT sales previously within Precious Metal Product and Fine Chemicals divisions

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
AGMOKODKOBKDBOB
Date   Source Headline
8th Jul 20259:55 amRNSHolding(s) in Company
1st Jul 20257:00 amRNSHolding(s) in Company
23rd Jun 20253:51 pmRNSHolding(s) in Company
20th Jun 20253:28 pmRNSDirector/PDMR Shareholding
17th Jun 20254:41 pmRNSHolding(s) in Company
12th Jun 20259:00 amRNSAnnual Financial Report - Part 2
11th Jun 20253:50 pmRNSHolding(s) in Company
6th Jun 20254:10 pmRNSHolding(s) in Company
5th Jun 20251:28 pmRNSHolding(s) in Company
4th Jun 20254:38 pmRNSHolding(s) in Company
30th May 20253:38 pmRNSHolding(s) in Company
28th May 20252:46 pmRNSHolding(s) in Company
27th May 20254:36 pmRNSHolding(s) in Company
27th May 20254:24 pmRNSHolding(s) in Company
27th May 20257:01 amRNSHolding(s) in Company
27th May 20257:00 amRNSHolding(s) in Company
22nd May 20255:09 pmRNSDirector/PDMR Shareholding
22nd May 20254:38 pmRNSHolding(s) in Company
22nd May 20257:01 amRNSJohnson Matthey Full Year Results
22nd May 20257:00 amRNSAgreement to sell Catalyst Technologies business
20th May 202510:35 amRNSHolding(s) in Company
19th May 20254:15 pmRNSHolding(s) in Company
19th May 20257:00 amRNSHolding(s) in Company
15th May 20255:53 pmRNSHolding(s) in Company
25th Apr 20252:43 pmRNSHolding(s) in Company
24th Apr 20253:28 pmRNSHolding(s) in Company
24th Apr 20258:00 amRNSHolding(s) in Company
17th Apr 20253:35 pmRNSDirector/PDMR Shareholding
26th Mar 20253:46 pmRNSHolding(s) in Company
25th Mar 20254:50 pmRNSHolding(s) in Company
24th Mar 20253:08 pmRNSHolding(s) in Company
21st Mar 20254:41 pmRNSHolding(s) in Company
20th Mar 202512:24 pmRNSDirector/PDMR Shareholding
14th Mar 20254:24 pmRNSHolding(s) in Company
13th Mar 20254:47 pmRNSHolding(s) in Company
12th Mar 20254:11 pmRNSHolding(s) in Company
11th Mar 20254:38 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSHolding(s) in Company
6th Mar 20255:18 pmRNSHolding(s) in Company
5th Mar 20257:00 amRNSHolding(s) in Company
4th Mar 20254:56 pmRNSHolding(s) in Company
3rd Mar 20255:12 pmRNSHolding(s) in Company
24th Feb 20255:08 pmRNSHolding(s) in Company
21st Feb 20253:40 pmRNSHolding(s) in Company
20th Feb 20252:46 pmRNSHolding(s) in Company
20th Feb 202510:57 amRNSDirector/PDMR Shareholding
19th Feb 20252:24 pmRNSHolding(s) in Company
13th Feb 20254:35 pmRNSDirector/PDMR Shareholding - replacement
13th Feb 20254:21 pmRNSDirector/PDMR Shareholding
13th Feb 202511:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.